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Abstract
Wnt signalling is a key pathway controlling bone formation in mice and humans. One of the regulators of this pathway is
Dkk1, which antagonizes Wnt signalling through the formation of a ternary complex with the transmembrane receptors
Krm1/2 and Lrp5/6, thereby blocking the induction of Wnt signalling by the latter ones. Here we show that Kremen-2 (Krm2)
is predominantly expressed in bone, and that its osteoblast-specific over-expression in transgenic mice (Col1a1-Krm2) results
in severe osteoporosis. Histomorphometric analysis revealed that osteoblast maturation and bone formation are disturbed
in Col1a1-Krm2 mice, whereas bone resorption is increased. In line with these findings, primary osteoblasts derived from
Col1a1-Krm2 mice display a cell-autonomous differentiation defect, impaired canonical Wnt signalling and decreased
production of the osteoclast inhibitory factor Opg. To determine whether the observed effects of Krm2 on bone remodeling
are physiologically relevant, we analyzed the skeletal phenotype of 24 weeks old Krm2-deficient mice and observed high
bone mass caused by a more than three-fold increase in bone formation. Taken together, these data identify Krm2 as a
regulator of bone remodeling and raise the possibility that antagonizing KRM2 might prove beneficial in patients with bone
loss disorders.
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Introduction
Bone is constantly remodelled through the activities of bone-
forming osteoblasts and bone-resorbing osteoclasts [1,2]. A relative
increase of bone resorption over bone formation can result in
osteoporosis, one of the most prevalent diseases in the aged
population [3,4]. It is therefore of hallmark clinical importance to
identify molecules specifically regulating the differentiation and
activity of osteoblasts, since these can potentially serve as targets
for osteoanabolic therapy. Moreover, as these molecules should be
accessible to drugs, they should ideally be located in the
extracellular space or at the cell surface, for instance as a receptor
for a given ligand. In this regard, the identification of the secreted
molecule SOST and the transmembrane protein LRP5 as
regulators of bone formation in humans was a major breakthrough
[5–9].
LRP5, together with LRP6, is the human orthologue of the
Drosophila protein arrow, which serves as a co-receptor for wingless,
the fly homologue of mammalian Wnt ligands [10]. Inactivating
mutations of the human LRP5 gene result in osteoporosis
pseudoglioma syndrome, and a similar phenotype has been
observed in mice with a targeted deletion of Lrp5 [5,11]. Likewise,
activating mutations of Lrp5 in mice and humans cause
osteosclerosis, a high bone mass disorder resulting from increased
osteoblast activity [6,7,12]. In addition, several investigators have
reported that specific single nucleotide polymorphisms within the
LRP5 gene are associated with decreased bone mineral density and
increased risk of osteoporotic fractures [13–15]. Based on this
cumulative evidence, but also due to its transmembrane
localization, LRP5 has been considered an excellent target
molecule for osteoanabolic therapy.
A second key regulator of bone formation in humans is the
secreted protein SOST, which is specifically produced by
osteocytes and acts as a negative regulator of osteblast activity
[16,17]. As it was the case for LRP5, the importance of the SOST
gene for bone mass was first uncovered by human genetics, where
it has been found that the loss of SOST expression or function
causes either van Buchem disease or sclerostosis, two related high
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Likewise, while Sost-deficient mice displayed osteosclerosis, an
osteoblast-specific over-expression of Sost resulted in an opposite
phenotype [17,18]. Most importantly however, albeit the Sost
protein is structurally related to a family of Bmp antagonists, it has
been shown to bind to the extracellular domain of Lrp5, thereby
inhibiting the activation of Wnt signalling pathways [19–22].
Taken together, these results have suggested that Wnt-
dependent signalling pathways are of crucial importance for
osteoblast biology, which is further underscored by the fact that
many mouse models with altered expression of proteins influenc-
ing Wnt binding and signal transduction display bone remodeling
phenotypes [23,24]. Among the several known modulators of Lrp5
activity, Dkk1, a member of the Dickkopf family of Wnt
antagonists, appears to be particularly interesting for several
reasons. First, although Dkk1 is indispensable for embryonic head
induction and limb development in mice, the postnatal analysis of
Dkk1 expression has revealed near specificity for differentiated
osteoblasts [25,26]. Second, while the homozygous deletion of
Dkk1 in mice causes embryonic lethality, the deletion of only one
Dkk1 allele results in an osteosclerotic phenotype, and the opposite
is observed in transgenic mice over-expressing Dkk1 [26,27].
Third, although there is no report so far for an impact of DKK1
mutations on bone mass in humans, there is hallmark evidence for
an over-production of DKK1 in human cancer cells being
responsible for the development of osteolytic lesions associated
with metastatic bone disease [28–33].
Albeit Dkk1 can inhibit Wnt signalling through a direct
interaction with Lrp5 or Lrp6, its antagonistic function is
significantly enhanced by members of the Kremen (Krm) family,
which serve as high affinity receptors for Dkk proteins [34,35].
Whether Krm proteins solely act as antagonists of Wnt signalling is
however questionable, since a positive influence on Lrp6-
dependent Wnt signaling has been described for Krm2, which is
possibly mediated through an interaction with Wnt signaling
activators of the Rspo family [36,37]. Here we show, that Krm2,
unlike Krm1, is predominantly expressed in bone, which led us to
generate transgenic mice over-expressing Krm2 specifically in
osteoblasts. These mice progressively developed an osteoporotic
phenotype, which was not only caused by impaired bone
formation, but also by increased bone resorption. Most impor-
tantly however, we observed that 24 weeks old Krm2-deficient
mice, which do not display a phenotype at younger age [38], are
characterized by a marked increase in bone formation. Taken
together, these data identify Krm2 as a regulator of bone
remodeling, at least in mice.
Results
Krm2 Expression in Bone
To uncover the potential relevance of Krm proteins in the
regulation of bone remodeling, we first analyzed the expression
pattern of the two known murine Krm genes and their potential
ligands of the Dkk and Rspo family by RT-PCR using cDNA from
tissues of 6 weeks old mice. Here we observed that Krm2, like Dkk1,
but unlike Krm1, is predominantly expressed in bone, thereby
suggesting a function in the regulation of osteoblasts and/or
osteoclasts (Figure 1A). A similar result was obtained, when we
used tissues from newborn mice, albeit we only detected Krm2
expression in calvarial bone, but not in the femur (Figure 1B). To
analyze bone expression on the protein level, we took advantage of
an antibody against the human KRM2 protein. Using immuno-
histochemistry on human bone sections we found that KRM2 is
specifically present in osteoblasts, but not in cells of the bone
marrow, albeit we also observed a weak staining of bone-resorbing
osteoclasts (Figure 1C).
Taken together, these findings led us to analyze the influence of
Krm2 on Wnt signaling in osteoblasts, which was first done in vitro
using the cell line MC3T3-E1, where we did not observe
endogenous expression of Krm2 (Figure 1B) and Dkk1 (data not
shown). Using DNA-transfection we observed that Dkk1 and
Krm2 antagonize the activation of a Wnt-responsive Luciferase
reporter gene, only when Wnt1 or Wnt3 expression plasmids are
co-transfected, but that Luciferase expression is increased by Krm2,
when a Wnt2 expression plasmid is used instead (Figure 1C).
Based on these conflicting results, we reasoned that it is virtually
impossible to analyze the role of Krm2 in osteoblasts in vitro. Thus,
we generated transgenic mice over-expressing Krm2 under the
control of an osteoblast-specific Col1a1 promoter fragment [39,40]
to determine, whether Krm2 has an influence on bone remodeling
in vivo, and if so, whether it is promoting or inhibiting osteoblast-
specific activites.
Generation of Col1a1-Krm2 Transgenic Mice
Three transgenic founder animals were identified by Southern
Blot hybridization (Figure 2A). One of these animals died at the
age of 10 weeks for unknown reasons, but its skeletal analysis
demonstrated a severe reduction of bone mass, with a near
absence of trabecular bone (Figure 2B). The two remaining
founder animals were viable, which enabled us to establish
independent transgenic lines. Since transgenic offspring of both
founders also displayed a striking decrease of the trabecular bone
volume at 10 weeks of age, we concluded that this phenotype is
indeed the consequence of Krm2 over-expression and not caused
by an insertional inactivation of other genes. Based on these results
we decided to focus on a founder line with an intermediate
transgene copy number (#1), which is termed Col1a1-Krm2 for the
remainder of the manuscript (Figure 2B). Here we first performed
RT-PCR to confirm the bone-specific expression of the transgene
(Figure 2C), and using Northern Blot hybridization we found that
the expression of Krm2 was at least 20-fold increased in bones from
transgenic animals (Figure 2D).
In order to analyze to skeletal phenotype of the Col1a1-Krm2
mice we first stained skeletons of one day old animals with alizarin
red and alcian blue, but we did not observe major defects of
skeletal patterning and growth in transgenic mice compared to
wildtype littermates (Figure 3A). Likewise, non-decalcified sections
of the spine did not reveal a significant difference of the trabecular
bone volume between newborn wildtype and transgenic mice
(Figure 3B). We therefore continued our study with the skeletal
analysis of older mice and first performed contact radiography,
where we failed to detect significant differences of skeletal growth
at 2 weeks of age (Figure 3C) and thereafter (Figure 3D).
Severe Osteoporosis in Col1a1-Krm2 Transgenic Mice
When we performed non-decalcified histology of vertebral body
sections, we observed that female Col1a1-Krm2 transgenic mice
progressively develop severe osteoporosis (Figure 4A). Albeit the
length of the lumbar spine was not reduced in transgenic mice
(Figure 4B), our histomorphometric quantification revealed a
decreased trabecular bone volume and trabecular number in
Col1a1-Krm2 mice at all ages, and a decreased trabecular thickness
at 24 weeks and 52 week of age (Figure 4B). The same phenotype
was observed in male transgenic mice, where we also found a more
than 4-fold reduction of the trabecular bone volume compared to
wildtype littermates at 24 weeks of age (data not shown).
Following mCT scanning of the vertebral bodies L6 (Figure 5A),
where we observed decreased trabecular bone mass, but normal
Kremen-2 and Bone Formation
PLoS ONE | www.plosone.org 2 April 2010 | Volume 5 | Issue 4 | e10309cortical thickness in Col1a1-Krm2 mice (data not shown), we
performed microcompression testing and found that the biome-
chanical stability of the vertebral bodies is largely reduced in
Col1a1-Krm2 mice, when compared to wildtype littermates
(Figure 4B). Cross-sectional mCT scans of the femora (Figure 4C)
further revealed reduced cortical thickness and bone mineral
content in Col1a1-Krm2 mice (Figure 4D), again accompanied by
reduced biomechanical competence in three-point-bending assays
(Figure 4E). In line with these findings, 2 out of 8 transgenic mice
older than 24 weeks (one male and one female) had to be sacrificed
due to spontaneous fractures, thereby demonstrating increased
bone fragility also in vivo (Figure 4F). Taken together, these
analyses revealed that Krm2 expression in osteoblasts has a
negative impact on bone integrity, which led us to perform
histomorphometry to determine, whether the severe osteoporosis
in Col1a1-Krm2 mice is caused by impaired bone formation and/or
bone resorption.
Krm2 Over-expression in Osteoblasts Impairs Bone
Formation
Although the histomorphometric quantification did not reveal
a significant difference of osteoblast numbers between wildtype
and transgenic mice, there was a striking effect of Krm2 over-
expression on osteoblast maturation and bone matrix deposition
Figure 1. Krm2 expression in osteoblasts. (A) RT-PCR expression analysis of Dkk, Krm and Rspo genes in primary osteoblasts (Obl. d5, non-
mineralized, Obl. d25, mineralized) and various tissues of 6 weeks old mice. (B) RT-PCR expression analysis of Krm genes in non-differentiated MC3T3-
E1 cells and tissues of newborn mice. (C) Immunohistochemistry on human bone sections reveals that KRM2 is present on osteoblasts lining the
trabecular bone surface (arrows, scale bars, 100 mm). The bottom panel shows staining of osteoclasts (scale bars, 20 mm). (D) DNA transfection in
MC3T3-E1 cells using expression plasmids for Wnt1, Wnt2 or Wnt3, Dkk1 and/or Krm2 at the indicated combinations. Bars represent mean 6 SD of
three independent experiments (n=9). Asterisks indicate statistically significant changes.
doi:10.1371/journal.pone.0010309.g001
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from transgenic mice displayed the regular morphology, and there
was a non-homogenous staining of mineralized bone compared to
sections from wildtype littermates. Likewise, when we looked at the
sections by fluorescence microscopy we observed that the number
of calcein-labelled surfaces, as well as the distance between calcein
labelling fronts was dramatically reduced in Col1a1-Krm2 mice
(Figure 6C). The quantification of these findings revealed that the
bone formation rate was nearly undetectable in Col1a1-Krm2 mice
at 6 and 24 weeks of age (Figure 6D). Interestingly, this near
abolishment of bone formation was not accompanied by changes
in the expression of well-established osteoblast differentiation
markers, such as Col1a1, Bglap or Ibsp (Figure 6E), which is further
underscored by the finding that serum osteocalcin levels and
alkaline phosphatase activities were not significantly decreased in 6
weeks old female Col1a1-Krm2 mice (Figure 6F).
Impaired Differentiation and Decreased Opg Production
in Primary Osteoblasts from Col1a1-Krm2 Transgenic
Mice
Taken together, these findings led us to analyze the
molecular differences between wildtype and transgenic osteo-
blasts, which were isolated from calvariae and differentiated ex
vivo.H e r ew eo b s e r v e dt h a t ,a l t h o u gh their proliferation rate
was significantly increased (Figure 7A), cultures from transgenic
mice displayed the expected decrease of extracellular matrix
mineralization after 10 days of differentiation (Figure 7B).
Moreover, when we stimulated primary osteoblasts with Wnt3a
we observed that the phosphorylation of Lrp6 was blunted in
cultures from transgenic mice (Figure 7C). Likewise, the
Wnt3a-dependent activation of canonical Wnt signaling,
assessed by decreased phosphorylation of ß-catenin, was
markedly reduced in transgenic cultures, as were the levels of
total ß-catenin. Since the expression of Tnfrsf11b,t h eg e n e
encoding the osteoclast-inhibitory factor Opg, is known to be
induced by canonical Wnt signaling in osteoblasts [41], we next
determined Opg production in osteoblasts from Col1a1-Krm2
mice and observed that it was reduced compared to wildtype
cultures, both by Western Blotting using cellular extracts and
by ELISA using conditioned medium (Figure 7D). Similar
results were obtained in vivo, where we found decreased
expression of Tnfrsf11b by quantitative RT-PCR, as well as
lower Opg serum concentrations in 6 weeks old female Col1a1-
Krm2 mice (Figure 7E).
Figure 2. Generation of Col1a1-Krm2 transgenic mice. (A) Schematic presentation of the construct used for osteoblast-specific over-expression of
Krm2 (top) and identification of three transgenic founder animals (arrows) by Southern Blotting (bottom), one of them dying at the age of 10 weeks. (B)
Von Kossa/van Gieson staining of non-decalcified vertebral body sections from 10 weeks old female wildtype mice (n=3), the dead founder animal (#2)
and age-matched female transgenic offspring from the two other founders (n=3, scale bars, 1 mm). The transgene copy numbers, as well as the
trabecular bone volume (BV/TV, bone volume per tissue volume) is given below. (C) Transgene-specific RT-PCR expression analysis revealing expression
in bone and weak expression in the eye. (D) Northern Blotting comparing Krm2 expression in transgenic mice compared to wildtype littermates.
doi:10.1371/journal.pone.0010309.g002
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Col1a1-Krm2 Mice
Based on these findings, we next analyzed the influence of Krm2
over-expression on bone resorption. Using TRAP activity staining
we found increased numbers of osteoclasts in spine sections from
transgenic mice (Figure 8A), which was subsequently confirmed by
histomorphometry (Figure 8B). Another important observation
was made, when we analyzed the Col1a1-Krm2 mice at the age of
52 weeks, where we found osteolytic lesions, that were especially
pronounced in the lower extremities (Figure 8C) and histologically
confirmed to be caused by a local activation of bone resorption
(Figure 8D). In addition, our histological analysis revealed several
sites of inappropriate de novo bone formation within the marrow
cavity of Col1a1-Krm2 mice (Figure 8E). Taken together, these
results demonstrated that Krm2, at least in mice, is a potent
inhibitor of bone formation, with an additional influence on bone
resorption, thereby underscoring the importance of Wnt signaling
in osteoblasts for both arms of bone remodeling.
Identification of differentially expressed genes in
Col1a1-Krm2 transgenic osteoblasts
To identify genes with a possible involvement in the cell-
autonomous defect of bone formation caused by the Krm2 over-
expression, we next performed Affymetrix Gene Chip hybridiza-
tion, where we applied samples from three independently isolated
wildtype and transgenic osteoblast cultures at day 10 of
differentiation (Figure 9A). While we did not observe altered
expression of several well-established osteoblast differentiation
Figure 3. Normal skeletal patterning and growth in Col1a1-Krm2 transgenic mice. (A) Staining of skeletons from one day old wildtype and
Col1a1-Krm2 transgenic littermates by alcian blue and alizarin red (scale bars, 5 mm). (B) Von Kossa/van Gieson staining of non-decalcified vertebral
body sections from one day old wildtype and Col1a1-Krm2 transgenic littermates (n=4, scale bars, 500 mm). The histomorphometric quantification of
the trabecular bone volume is given below. (C) Contact Xrays of 2 weeks old female wildtype and Col1a1-Krm2 transgenic littermates (scale bars,
1 cm). (D) Determination of the femur and tibia length of female wildtype and Col1a1-Krm2 transgenic littermates at the indicated ages. Bars
represent mean 6 SD (n=6).
doi:10.1371/journal.pone.0010309.g003
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transgenic cultures, our analysis revealed significantly reduced
expression of specific genes, albeit only few of them can potentially
explain the severe impairment of bone formation caused by Krm2
over-expression. These included Dmp1 [42], Phex [43], the three
genes encoding type-IX-collagen [44], Smpd3 [45], and Pcolce2, the
latter one encoding an enhancer of procollagen processing [46]. In
addition, the expression of Tnfsf11, encoding the osteoclast
differentiation factor Rankl, was higher in transgenic osteoblasts,
whereas the expression of Tnfrsf11b was decreased.
To address the question, whether these genes are direct targets
of Dkk1, we compared these results to another Affymetrix Gene
Chip hybridization experiment, where we treated wildtype
osteoblasts with Dkk1 for 6 hours. In line with the findings in
Col1a1-Krm2 osteoblasts we did not observe an effect of Dkk1 on
the expression of Runx2, Sp7, Alpl, Col1a1, Bglap, Ibsp and Spp1
(data not shown), but we did observe a reduced expression of
Smpd3 and Tnfrsf11b following Dkk1 treatment (Figure 9B).
Moreover, nearly all of the 25 genes showing the strongest
down-regulation by Dkk1 were also expressed at lower levels in
Col1a1-Krm2 osteoblasts. In contrast however, Dkk1 administration
did not have an immediate effect on the expression of Dmp1, Phex,
Col9a1-3 and Pcolce2 (data not shown) thereby suggesting that some
of the molecular differences between wildtype and Col1a1-Krm2
osteoblasts may be caused either indirectly or independent of
Dkk1.
High Bone Mass in Mice Lacking Krm2
Given the potential importance of these findings for the
treatment of bone loss disorders, we finally addressed the
question, whether the observed effects of Krm2 are physiolog-
ically relevant. To achieve this goal, we analyzed vertebral bodies
of 24 weeks old Krm2-deficient mice, since the previous analysis of
tibia sections at the age of 12 weeks did not reveal a significant
Figure 4. Decreased trabecular bone mass in Col1a1-Krm2 transgenic mice. (A) Von Kossa/van Gieson staining of non-decalcified vertebral
body sections from female wildtype and Col1a1-Krm2 transgenic littermates at the indicated ages (scale bars, 1 mm). (B) Determination of the lumbar
spine length. (C) Histomorphometric quantification of the trabecular bone volume, trabecular number (Tb.N.) and trabecular thickness (Tb.Th.). All
bars represent mean 6 SD (n=6). Asterisks indicate statistically significant differences.
doi:10.1371/journal.pone.0010309.g004
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Here we found that 24 weeks old Krm2-deficient mice displayed a
significantly increased trabecular bone mass (Figure 10A),
together with an increased number of single- and double-labeled
bone surfaces following dual calcein injection (Figure 10B). Using
histomorphometry we were able to confirm the increase of the
trabecular bone volume, but we failed to detect a defect of
osteoclast formation in Krm2-deficient mice at 24 weeks of age
(Figure 10C). In contrast, the osteoblast surface was significantly
higher in Krm2-deficient mice, and most importantly, the bone
formation rate was more than three-fold increased compared to
wildtype littermates (Figure 10D). Moreover, unlike it was the
case at the age of 12 weeks, 24 weeks old animals Krm2-deficient
mice also displayed an increased trabecular bone volume in the
tibia (Figure 10E,F). Taken together, these results demonstrate
that Krm2, at least in mice, is an endogenous inhibitor of bone
formation.
Discussion
Although osteoporosis is one of the most prevalent diseases in
the aged population, the options for its treatment are still limited
[47]. This is especially true for agents stimulating the activity of
osteoblasts, which explains why the discovery of LRP5 and SOST
as regulators of bone formation in humans was considered to be of
hallmark clinical importance [5–9]. Here we show, that the
transmembrane protein Krm2, which serves as a receptor for Wnt
antagonists of the Dkk family [34], is another physiological
regulator of bone formation, at least in mice. In fact, Col1a1-Krm2
transgenic mice display a severe osteoporotic phenotype, resulting
in reduced biomechanical stability of both, vertebral bodies and
long bones. This can be primarily explained by a decreased
trabecular bone mass, whereas cortical thickness was only found
affected in femora, but not in the spine, which might be explained
by different strain distributions between the two skeletal elements.
Most importantly however, Krm2-deficient mice also display a high
Figure 5. Decreased biomechanical stability of bones from Col1a1-Krm2 transgenic mice. (A) mCT scanning of the vertebral bodies L6 from
24 weeks old female wildtype and Col1a1-Krm2 transgenic littermates (scale bars, 1 mm). (B) Microcompression testing revealed reduced
biomechanical stability (Fmax, maximal force until bone failure). Bars represent mean 6 SD (n=6). Asterisks indicate statistically significant
differences. (C) mCT scanning of the femora showing reduced cortical thickness and impaired mineralization (scale bars, 500 mm). (D) Cortical
thickness (C.Th.) and bone mineral density (vBMD) are decreased in Col1a1-Krm2 transgenic mice compared to wildtype littermates. Bars represent
mean 6 SD (n=6). Asterisks indicate statistically significant differences. (E) Three-point bending assays reveal reduced biomechanical competence of
transgenic femora. Bars represent mean 6 SD (n=12). Asterisks indicate statistically significant differences. (F) Xray analysis of a 30 weeks old male
Col1a1-Krm2 transgenic mouse with a spontaneous tibia fracture (arrow) compared to a non-transgenic littermate (scale bars, 2 mm).
doi:10.1371/journal.pone.0010309.g005
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especially relevant given the absence of obvious abnormalities
outside the skeleton. Based on these arguments, it appears that
Krm2 has a specific function in bone remodeling, thereby raising
the possibility that KRM2 might serve as an ideal target for
osteoanabolic therapy, if it exerts a similar function in humans. In
this regard, it is important to state that an over-expression of Krm2
in osteoblasts also causes an activation of bone resorption, which
implies that a putative KRM2 antagonist might have a possible
influence on both arms of bone remodeling.
Albeit our results obtained in two genetically modified mouse
models confirm that an antagonism of Wnt signaling in osteoblasts
has a negative effect on bone formation, they were not necessarily
expected, based on several findings published by others. First,
while mice lacking one allele of Dkk1 display the expected high
bone mass phenotype, Dkk2-deficient mice are characterized by
reduced bone formation and osteopenia, thereby demonstrating
that these two Krm2 ligands do not mediate the same effects on
osteoblasts in vivo [48]. Second, while bone mass is unaffected in
mice lacking Lrp5 specifically in osteoblasts, a gut-specific deletion
Figure 6. Impaired bone formation in Col1a1-Krm2 transgenic mice. (A) Toluidine blue staining of non-decalcified vertebral body sections
from 6 weeks old female wildtype and Col1a1-Krm2 transgenic littermates revealing that the normal appearance of cuboidal osteoblasts (arrows)
covering trabecular bone surfaces is only observed in wildtype controls (scale bars, 50 mm). (B) Histomorphometric quantification showing that the
number of osteoblasts (ObN/BPm, osteoblast number per bone perimeter) is not significantly decreased in sections from transgenic mice. (C)
Fluorescent micrographs showing that overall calcein labeling is reduced in vertebral bodies of 6 weeks old female Col1a1-Krm2 transgenic mice (top,
scale bars, 1 mm), as is the distance between the labeled surfaces at endosteal bone surfaces of the tibia (bottom, scale bars, 20 mm). (D)
Histomorphometric quantification of the bone formation rate (BFR/BS, bone formation rate per bone surface) in female wildtype and Col1a1-Krm2
transgenic littermates. (E) Northern Blot expression analysis for Col1a1, Bglap and Ibsp using femur RNA of 6 weeks old female wildtype and
transgenic mice. (F) Serum levels of osteocalcin and activities of alkaline phosphatase in 6 weeks old female wildtype and transgenic mice. All bars
represent mean 6 SD (n=6). Asterisks indicate statistically significant differences.
doi:10.1371/journal.pone.0010309.g006
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consequence of increased serotonin production, thus implying that
Lrp5 does not control bone formation in a cell-autonomous
manner [49]. Third, mice harbouring an osteoblast-specific
inactivation of ß-catenin, the major intracellular mediator of
Wnt signalling, displayed normal bone formation, but increased
bone resorption, which was molecularly explained by reduced
production of the osteoclast-inhibitory factor Opg [41]. Taken
together, these two latter findings have challenged the concept that
Wnt signalling in osteoblasts is a key pathway for the regulation of
bone formation, which was further underscored by the finding that
the osteopenia of rs/rs mice, carrying a hypomorphic mutation of
the Wnt co-receptor Lrp6, is caused by increased bone resorption
[50].
In this regard, it was not only an important, but also an
unexpected observation, that the osteoblast-specific antagonism of
Wnt signalling achieved through transgenic over-expression of
Krm2 has such a tremendous impact on bone formation, thereby
causing an osteoporotic phenotype, whose severity exceeds the one
observed in Lrp5-deficient mice [11]. In fact, our finding that bone
formation was nearly abolished in the Col1a1-Krm2 transgenic mice
underscores the importance of intact Wnt signalling for the
endogenous regulation of osteoblast differentation and function.
Another interesting and unexpected observation was that the
severe impairment of bone formation in Col1a1-Krm2 mice
occurred despite nearly normal expression levels of several well-
established osteoblast differentiation markers, which was con-
firmed by a genome-wide comparative expression analysis using
three independently isolated osteoblast cultures from wildtype and
Col1a1-Krm2 transgenic mice. Since we did observe a cell-
autonomous defect of matrix mineralization in primary osteoblasts
from Col1a1-Krm2 mice however, we were further able to identify
specific genes, whose reduced expression can possibly explain the
severe impairment of bone formation in Col1a1-Krm2 mice. These
included Dmp1 and Phex, two genes required for bone matrix
mineralization and phosphate homeostasis (41,42), but also the
three genes encoding type IX collagen, which is potentially
important, since Col9a1-deficient mice have recently been
described to display an osteoporotic phenotype [44]. However,
since we only observed a moderate increase in the volume of non-
mineralized osteoid in Col1a1-Krm2 mice, together with normal
serum phosphate levels (data not shown), and since the
osteoporotic phenotype of Col9a1
+/2 mice is rather caused by
increased bone resorption [44], we believe that the reduced
expression of other genes is more likely to explain the near absence
of bone formation in Col1a1-Krm2 mice.
Of particular interest in this regard is Smpd3, encoding one
member of the sphingomyelin phosphodiesterase family, cleaving
sphingomyelin into ceramide [51]. Although the precise mecha-
nism of its action in osteoblasts remains to be established, a
deletion within the Smpd3 gene has been found in a chemically
induced mutant mouse model termed fragilis ossium (fro) [45]. The
Figure 7. Cell-autonomous defect of Col1a1-Krm2 transgenic osteoblasts. (A) BrdU incorporation assays revealed a higher proliferation rate
in primary calvarial osteoblast cultures from transgenic mice after 2 days of differentiation. (B) Von Kossa staining performed at 10 days of
differentiation reveals reduced mineralization of osteoblasts from Col1a1-Krm2 mice (scale bars, 1 cm), despite higher protein content (given below).
Values represent mean 6 SD (n=3). Asterisks indicate statistically significant differences. (C) Western Blot analysis of canonical Wnt signaling using
primary osteoblasts from wildtype and transgenic mice following stimulation with Wnt3a for 30 minutes. (D) Western Blot analysis (left) and ELISA
(right) showing decreased Opg levels in cellular extracts and conditioned medium of osteoblasts from Col1a1-Krm2 mice. (E) Quantitative RT-PCR
(left) and ELISA (right) demonstrating that the reduced expression of Tnfrsf11b in bones of 6 weeks old Col1a1-Krm2 mice results in decreased Opg
serum levels. All bars represent mean 6 SD (n=4). Asterisks indicate statistically significant differences.
doi:10.1371/journal.pone.0010309.g007
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imperfecta (OI), a genetic disease of impaired bone matrix
deposition and increased fracture risk [52]. However, unlike what
is the case in the vast majority of OI cases, fro/fro mice do not
display any detectable collagen synthesis defect, thereby suggesting
that sphingomyelin degradation may be a key factor regulating
formation and mineralization of the bone matrix, independent of
collagen production [53,54]. In this regard it is also interesting that
another gene with significantly reduced expression in osteoblasts
from Col1a1-Krm2 mice, namely Pcolce2, has been described to
serve a function as an enhancer of C-terminal procollagen
processing [46]. Whether this function is also relevant for the
posttranslational modification of type I collagen in osteoblasts
remains to be established, since mice lacking Pcolce2 have not been
analyzed for their skeletal phenotype so far [55].
Given the fact, that the phenotype of Col1a1-Krm2 mice is
apparently more severe than the phenotype of Col1a1-Dkk1
transgenic mice reported in the literature [26], it was also
important to compare the genome-wide expression analysis of
wildtype and Col1a1-Krm2 transgenic osteoblasts to another Gene
Chip hybridization experiment, where we have treated wildtype
osteoblasts with Dkk1 for 6 hours. Interestingly, the data
obtained here confirmed that the majority of genes being
repressed following Dkk1 administration were also expressed at
lower levels in osteoblasts from Col1a1-Krm2 mice. In contrast
however, we did not find an influence of Dkk1 on the expression
Figure 8. Increased bone resorption in Col1a1-Krm2 transgenic mice. (A) TRAP activity staining for osteoclasts (arrows) in decalcified vertebral
body sections from 6 weeks old female wildtype and Col1a1-Krm2 transgenic mice (scale bars, 50 mm). (B) Histomorphometric quantification
confirmed the increased number of osteoclasts (OcN/BPm, osteoclast number per bone perimeter) in transgenic mice. Bars represent mean 6 SD
(n=6). Asterisks indicate statistically significant differences. (C) Xray analysis (top, scale bars, 1 mm) and mCT scanning (bottom, scale bars, 2 mm)
demonstrating the presence of osteolytic lesions in 52 weeks old female Col1a1-Krm2 mice. (D) Goldner staining of the tibia showing osteoclasts at
sites of cortical bone erosion (arrowheads), but also inappropriate bone formation in the marrow cavity of 52 weeks old female transgenic mice
(arrows, scale bars, 100 mm). (E) Von Kossa/van Gieson staining reveals that the inappropriate bone formation in 52 weeks old female Col1a1-Krm2
mice is associated with an accumulation of non-mineralized osteoid (stained in red, scale bars, 100 mm).
doi:10.1371/journal.pone.0010309.g008
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This suggests that Krm2 might also exert Dkk1-independent
functions, and that future experiments should aim at the
identification of other signaling pathways that might be affected
by Krm2. In addition, it might be worthwhile to analyze the
expression of Smpd3 and Tnfrsf11b in osteoblasts from Col1a1-
Dkk1 mice. In this regard, it is especially surprising that the
Col1a1-Dkk1 mice do not display increased bone resorption, since
a negative influence of Dkk1 on Opg production has also been
reported by others [56,57].
Regardless of the precise mechanism underlying the effects of
Krm2 on bone remodeling however, we believe that the most
important question is whether the deduced functions of Krm2 are
also physiologically relevant. The potential role of the two known
Krm genes in bone remodeling has recently been addressed
through the analysis of the respective mouse deficiency models
[38]. Not necessarily expected, both mouse models were viable
and fertile and neither displayed obvious abnormalities, nor
premature mortality. The same was the case for mice lacking both
Krm genes, thereby demonstrating that Krm-dependent signalling
Figure 9. Differentially expressed genes in Col1a1-Krm2 transgenic osteoblasts. (A) Affymetrix Gene Chip hybridization demonstrates that
several well-established osteoblast differentiation markers are expressed at similar levels in osteoblasts from wildtype (mean values indicated by the
dotted red line) and transgenic mice, while other genes are expressed at lower levels in the latter ones. Bars represent mean 6 SD (n=3). Asterisks
indicate statistically significant differences between the relative signal intensities in wildtype and transgenic samples. (B) Affymetrix Gene Chip
hybridization of wildtype osteoblasts following treatment with Dkk1 for 6 hours at day 10 of differentiation (n=1). Shown are the Affymetrix signal
intensities and the signal log ratios (SLR) for the 25 genes displaying the strongest negative regulation by Dkk1. The mean signal ratios of the Gene
Chip comparison between wildtype and Col1a1-Krm2 transgenic osteoblasts are given on the right.
doi:10.1371/journal.pone.0010309.g009
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ical processes. A histomorphometric analysis of bone remodeling,
performed in tibia sections of 12 weeks old Krm1- and Krm2-
deficient mice, revealed no significant difference compared to
wildtype littermates. However, the combined deficiency of both
Krm genes resulted in increased bone formation and osteosclerosis,
thereby suggesting a physiological influence of Krm1 and Krm2
on bone formation with functional redundancy.
Based on our findings obtained in the Col1a1-Krm2 transgenic
mice we have now expanded the analysis of Krm2-deficient mice to
24 weeks of age and observed a marked increase of the trabecular
bone volume compared to wildtype littermates, which is caused by a
more than three-fold increase of bone formation. In contrast to the
results obtained in the transgenic animals however, we did not
observe a difference in osteoclast number, eroded surface or in the
serum concentrations of carboxyterminal collagen crosslinks (data
not shown) between wildtype and Krm2-deficient littermates. It is
possible that these changes would appear with time, since our own
experience, not only with the Col1a1-Krm2 mice, but also with Calca-
or Cckbr-deficient mice for instance, raises the possibility, that severe
bone resorption phenotypes, such as osteolyses, rather develop in
aged mice [58,59]. In this regard it will be interesting to study the
skeletalphenotypeofKrm2-deficient micebeingolderthanoneyear,
and it may be worthwhile to analyze the possibility that these mice
are protected from tumor-induced osteolytic lesions. Another
possibility explaining the absence of a bone resorption phenotype
in 24 weeks old Krm2-deficient mice would be that the regulation of
osteoclastogenesis is compensated by Krm1. To address this
question it will be important to analyze 24 weeks old mice lacking
either Krm1 alone, or both murine Krm genes in future experiments.
Regardless of the outcome from this analysis however, the results
presented in this manuscript provide important and novel in vivo
evidence for a specific role of Krm2 in the regulation of osteoblast
differentiation and activity, at least in mice.
Figure 10. Increased bone formation in Krm2-deficient mice. (A) Von Kossa/van Gieson staining of non-decalcified vertebral body sections
from 24 weeks old female wildtype (Krm2
+/+) and Krm2-deficient (Krm2
2/2) mice (scale bars, 1 mm). (B) Fluorescent micrographs showing a higher
number of calcein-labelled surfaces in Krm2-deficient vertebral bodies (scale bars, 200 mm). (C) Histomorphometric quantification of the trabecular
bone volume and osteoclast surface per bone surface (OcS/BS). (D) Histomorphometric quantification of the osteoblast surface per bone surface
(ObS/BS) and the bone formation rate. (E) Von Kossa/van Gieson staining of non-decalcified tibia sections from 24 weeks old female wildtype and
Krm2-deficient mice (scale bars, 1 mm). (F) Histomorphometric quantification of the trabecular bone volume and the trabecular number. All bars
represent mean 6 SD (n=6). Asterisks indicate statistically significant differences.
doi:10.1371/journal.pone.0010309.g010
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Expression Analysis
RNA from mouse tissues, primary osteoblasts and MC3T3-E1
cells was isolated using the Trizol reagent (Invitrogen) and reverse
transcribed using the Cloned AMV First-Strand cDNA synthesis
kit (Invitrogen). PCR was performed with gene-specific primers for
Dkk1 (59-CCA CAC CTG CCA GAG ACA CTA AAC-39and 59-
GGG GAG TTC CAT CAA GAA ACA AAG-39), Dkk2 (59-CCT
ACT CTT CCA AAG CCA GAC TCC-39and 59-TGA CAA
TCT GAA GGA AAT GCC-39), Dkk3 (59-TAG GCG GAG AGG
AGG AGA TTT AGG-39 and 59-GGT TAC ATT TTG CCA
AGT CCA CG-39), Krm1 (59-AAC GAG ACT TTC CAG CAT
CCG-39and 59-TCC ATC CCA GCA AAC TTG AAT C-39),
Krm2 (59-TGG GTT CCT ACA GAA GTT ATG CG-39and 59-
CGT CCA AGG CAC CAT CTC TTT G-39), Rspo1 (59-ACC
TGG ATA CTT TGA TGC CCG-39and 59-CGC TCA TTT
CAC ATT GTG CAG9), Rspo2 (59-GAA GTT GGT CAT TGG
AGC GAA-39and 59-TGC CTT TGG TGT TCT CTT TCC
T9), Rspo3 (59-AAA GTG CCT TGA CAG TTG CGC-39 and 59-
TCC TCG CTC TCC CTT TGA ACA C-3)and Gapdh (59-GAC
ATC AAG AAG GTG GTG AAG CAG-39 and 59-CTC CTG
TTA TTA TGG GGG TCT GG-39), and the identity of amplified
fragments was verified by automatic sequencing. Northern Blot
analysis was carried out according to standard protocols [60]. For
the genome-wide expression analysis, RNA was subjected to
hybridization of Affymetrix Gene Chips (MG 430 2.0) according
to the manufacturer’s protocol. Absolute and comparison analyses
were performed with Affymetrix MAS algorithm using default
parameters. Quantitative RT-PCR analysis was performed using a
StepOnePlus system, predesigned TaqMan gene expression
assays, and TaqMan gene expression mastermix (Applied
Biosystems). Gapdh and B2m expression was used as internal
controls. Relative quantification was performed according to the
DDCT method, and results were expressed in the linear form using
the formula 2
2DDCT.
Human Bone Biopsies
A collection of biopsies from healthy individuals and from
patients with various bone disorders has been established at the
Hamburg University over the last decades [61]. Immunohisto-
chemistry was performed on decalcified sections from skeletal-
intact donors using a polyclonal antibody against human KRM2
(Sigma, #HPA003223) following standard protocols.
DNA Transfection
The three different Wnt expression plasmids were kindly
provided by Dr. J. Kitajewski (New York, USA), the Krm2
expression plasmid has been described previously [34], and the
Dkk1 expression plasmid was constructed by placing the full-length
cDNA into the vector pCMV-Tag4 (Stratagene). In all exper-
iments the Wnt-responsive reporter plasmid TOPflash (Upstate,
#21-170) was co-transfected with a CMV-driven ß-Galactosidase
reporter plasmid (kindly provided by Dr. P. Ducy, New York,
USA) to normalize for transfection efficiency. DNA-cotransfection
was performed in MC3T3-E1 cells (ATCC, #CRL-2593) using
calcium phosphate transfection, and the activities of Luciferase
and ß-Galactosidase were measured two days later as described
[62].
Mice
For the generation of Col1a1-Krm2 transgenic mice the ORF
encoding Krm2 was placed under the control of an osteoblast-
specific 2.3kb Col1a1 promoter fragment (kindly provided by Dr.
B. de Crombrugghe, Houston, USA). Pronucleus injection into
fertilized oocytes was performed according to standard protocols.
Genotyping of the offspring was performed by Southern Blotting
following digestion with Kpn I using the 39-UTR of the hGH gene
as a probe, or by PCR using primers located within the ß-globin
intron and the Krm2 cDNA. To determine the transgene copy
number genomic DNA was digested with Kpn I and probed with a
Kpn I-fragment of the Krm2 cDNA, which detected a transgenic
fragment of 888 bp and an endogenous fragment of 3.5 kb.
Transgene expression was monitored by RT-PCR using primers
within the Krm2 cDNA and the 39-UTR of the hGH gene. The
generation of Krm2-deficient mice has been described previously
[38]. All animal experiments were approved by the animal facility
of the University Medical Center Hamburg-Eppendorf and by the
‘‘Amt fu ¨r Gesundheit und Verbraucherschutz’’ (35/04, Org139).
Skeletal Analysis
Before their skeletal analysis all mice received two injections of
calcein (9 and 2 days before sacrifice). After their initial analysis by
contact Xray (Faxitron Xray Corp.), the vertebral bodies L2 to L5
and one tibia from each animal were dehydrated and embedded
non-decalcified into methylmetacrylate for sectioning. Sections
were either stained with toluidine blue, by the von Kossa/van
Gieson procedure, or by Goldner staining as described [58]. mCT
scanning was performed with vertebral bodies L6 and with femora
using a mCT 40 device (Scanco Medical, Switzerland). Biome-
chanical stability was assessed by microcompression testing for
vertebral bodies and by three-point bending assays for femora
using a Z2.5/TN1S-device (Zwick) [59]. Staining of skeletons from
newborn mice with alcian blue and alizarin red was performed as
described [60].
Quantification of Bone Remodeling
Static and cellular histomorphometry was carried out on
toluidine blue-stained sections using the OsteoMeasure system
(Osteometrics, Decatur, USA) following the guidelines of the
American Society of Bone and Mineral Research [63]. Dynamic
histomorphometry for determination of the bone formation rate
was performed on two consecutive non-stained 12mm-sections.
TRAP activity staining was performed on decalcified sections
using napthol AS-MX phosphate (Sigma, #N-5000) and Fast Red
Violet LB salt (Sigma, #F-3881) in 40 mM acetate buffer (pH5).
Serum levels of Osteocalcin and Opg were determined by RIA
(Immutopics, #50-1300) and ELISA (R&D Systems, #MOP00),
respectively. Serum alkaline phosphatase activities were measured
using p-nitrophenylphosphate as a substrate (Pointe Scientific,
#A7516).
Cell culture
Primary osteoblasts were isolated from the calvariae of 5 days
old mice and differentiated ex vivo by the addition of ascorbic acid
(50 mg/ml) and ß-glycerophosphate (10 mM). BrdU incorporation
assays were performed at day 2 of differentiation using the Cell
Proliferation Biotrak ELISA (GE Healthcare, #RON250), while
extracellular matrix mineralization was assessed at day 10 of
differentiation using von Kossa-staining [60]. To demonstrate
impaired Wnt signaling serum-starved cells were treated for
30 minutes with 100 ng/ml recombinant Wnt3a (R&D systems,
#1224-WN-002), and whole cell lysates were subsequently used
for Western Blotting using antibodies against phospho-Lrp6 (Cell
Signaling, #2568), phospho-ß-catenin (Cell Signaling, #9561),
total ß-catenin (Santa Cruz, #E2808), Opg (R&D Systems,
#AF459) and ß-actin (Sigma, #A2228). To identify Dkk1-
regulated genes, primary osteoblasts were serum-starved over
Kremen-2 and Bone Formation
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Systems, #5897-DK-1010) for 6 hours before the RNA was
isolated as described above.
Statistical Analysis
Results are presented as means 6 standard deviations.
Statistical analysis was performed using unpaired, two-tailed
Student’s t test, and p-values below 0.05 were considered
statistically significant.
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